Cargando…

Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime

BACKGROUND: Revised National Tuberculosis Control Programme (RNTCP) of Government of India provides intermittent thrice-a-week directly observed treatment short course (RNTCP regimen). OBJECTIVE: Assessments of all-cause mortality and nine-month morbidity outcomes of patients with tuberculous mening...

Descripción completa

Detalles Bibliográficos
Autores principales: Iype, Thomas, Pillai, Ayyappan Kunjukrishna, Cherian, Ajith, Nujum, Zinia T., Pushpa, Chithra, Dae, Dalus, Krishnapillai, Vijayakumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162013/
https://www.ncbi.nlm.nih.gov/pubmed/25221396
http://dx.doi.org/10.4103/0972-2327.138496
Descripción
Sumario:BACKGROUND: Revised National Tuberculosis Control Programme (RNTCP) of Government of India provides intermittent thrice-a-week directly observed treatment short course (RNTCP regimen). OBJECTIVE: Assessments of all-cause mortality and nine-month morbidity outcomes of patients with tuberculous meningitis (TBM) on RNTCP regimen. MATERIALS AND METHODS: We prospectively followed up patients registered with RNTCP center, with a diagnosis of TBM from January 1(st), 2010 to December 31(st), 2011. Morbidity was assessed using modified Rankin Scale (mRS). RESULTS: We had 43 patients with median duration for follow-up of 396 days and that of survivors of 425 days. Two patients defaulted. Fourteen patients (32.5%) had mRS score of 4 to 6 and 29 had mRS of 0 to 3 after 9-month treatment. Severe disability was not related to any factor on logistic regression. Severe disability was seen in one patient (6.66%) among the 15 patients with stage 1, nine (37.5%) out of 24 patients with stage 2 and three (75%) out of 4 patients with stage 3 disease. Eight patients died (18.6%) of whom 4 died during the intensive phase and 4 during the continuation phase of RNTCP regimen. Mortality was independently related to treatment failure with adjusted Hazard ratio of 8.29 (CI: 1.38-49.78) (P = 0.02). One patient (6.66%) died out of the 15 patients with stage 1 disease, 5 (20.8%) out of 24 patients with stage 2 disease and 2 (50%) out of the 4 with stage 3 disease. DISCUSSION AND CONCLUSION: RNTCP regimen was associated with good compliance, comparable mortality and morbidity.